Aernoud Fiolet

143 Colchicine in Patients with Chronic Coronary Disease noncardiovascular death or the regular end of trial. On‑treatment Kaplan–Meier and Cox proportional-hazards models were performed by imposing additional censoring at 30 days after (premature) permanent discontinuation of trial medication. No formal hypothesis testing was performed for the on-treatment analysis. The first patient was enrolled in the LoDoCo2 trial on 4 th August 2014. On 3 rd November 2018 the last patient entered the open label run-in phase and on 3 rd December 2018 the last patient was randomized. The last participant follow-up contact occurred on 17 th February 2020. The database was locked on 22 nd May 2020. All statistical analyses were performed with use of SAS software, version 9.4 (SAS Institute) and with use of R software version 3.6.0. 1